CROI 2023: Yet more evidence for recycled tenofovir and 3TC or FTC with dolutegravir in second-line: 48 week results from the D2EFT study
10 March 2023. Related: Conference reports, Treatment strategies, Drug resistance.
2023
CROI 2023: Point-of-care testing for mothers and infants: results from the LIFE study
10 March 2023. Related: Conference reports, Pregnancy, Paediatric care.
CROI 2023: Bone density profiles for CAB-LA vs TDF/FTC oral PrEP in young adults
10 March 2023. Related: Conference reports, Side effects, HIV prevention and transmission.
CROI 2023: Single dose doxycycline as PEP for STIs (doxy-PEP): five studies
10 March 2023. Related: Conference reports, Coinfections and complications.
CROI 2023: Severe mpox outcomes with a low CD4 count and detectable viral load: a new AIDS-defining condition?
10 March 2023. Related: Conference reports, mpox (monkeypox).
The Düsseldorf patient HIV cure case published in Nature Medicine
10 March 2023. Related: Cure-related research.
UK-CAB online training: webinar programme every two weeks
10 March 2023. Related: Treatment advocacy, On the web.
New community platform on HIV and mental health: in 10 EU languages
1 March 2023. Related: Treatment advocacy, Other news.
HTB: no. 3 (March 2023) PDF download
1 March 2023. Related: PDFs.
Supporting Ukraine
1 March 2023. Related: Editorial.
HTB: no. 1/2 (January/February 2023) PDF download
1 February 2023. Related: PDFs.
HTB January/February 2023 (1 February 2023)
1 February 2023. Related: Editorial.
24th International Workshop on Long-term Complication of HIV and SARS-CoV-2
1 February 2023. Related: On the web.
30th Conference on Retroviruses and Opportunistic Infection (CROI 2023)
1 February 2023. Related: Conference reports.
Glasgow HIV Congress (2022)
1 February 2023. Related: Conference reports.
Glasgow 2022: pipeline studies with bNAbs N6LS and maturation inhibitor GSK254
1 February 2023. Related: Conference reports, Antiretrovirals.
Glasgow 2022: doravirine updates
1 February 2023. Related: Conference reports, Antiretrovirals.
Glasgow 2022: long-acting cabotegravir/rilpivirine: adverse events, implementation and PROMs
1 February 2023. Related: Conference reports, Antiretrovirals.
Glasgow 2022: community statement on HIV and ageing
1 February 2023. Related: Conference reports, Ageing and life expectancy, Treatment advocacy.
Lenacapavir approved in the US for multidrug resistant HIV
1 February 2023. Related: Antiretrovirals.
More evidence for recycling tenofovir in second-line ART with dolutegravir: 72-week results from ARTIST study
1 February 2023. Related: Antiretrovirals, Treatment strategies.
Low level viral load on effective ART is linked to clonal expansion of reservoir: not affected by modifying ART
1 February 2023. Related: Antiretrovirals, Treatment strategies, Guidelines, Drug resistance.
Integrase inhibitors associated with higher increases in CD4:CD8 ratio than PI- or NNRTI-based ART
1 February 2023. Related: Antiretrovirals, Treatment strategies.
Superinfection detected in up to 7% of people in Swiss HIV Cohort Study
1 February 2023. Related: Coinfections and complications, Drug resistance.
Zero transmission in France for mothers on ART from conception with undetectable viral load at delivery
1 February 2023. Related: Pregnancy.
Phase 3 Mosaico HIV vaccine efficacy trial stopped early due to lack of benefit
1 February 2023. Related: Vaccines and microbicides.
Update on mpox: sleeping or hiding?
1 February 2023. Related: mpox (monkeypox).
56 Dean Street as a nurse-led PrEP clinic: >20,000 clients in 2021
1 February 2023. Related: HIV prevention and transmission.
Potential to use BOTOX for erectile dysfunction
1 February 2023. Related: Coinfections and complications.
Cases of Kaposi’s Sarcoma (KS) in people on effective ART
1 February 2023. Related: Coinfections and complications.
Shorter course of less-intensive treatment for visceral leishmaniasis
1 February 2023. Related: Coinfections and complications.